Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

The CRISPR gene editing system holds tremendous promise. It has already revolutionized biomedical research by making gene editing a straightforward process. It involves using a guide RNA molecule that ...

Researchers at ETH Zurich in Basel report they have used CRISPR-Cas technology to decipher how mutations in a cell’s genome affect its function. With their new approach, the researchers can generate ...

Prime Medicine has surged over 130% in three months, driven by pipeline progress and visibility from recent scientific presentations. PRME's Prime Editing platform targets multi-billion-dollar markets ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...

Using prime editing, NCF1 mutation is corrected in a 19-year-old with chronic granulomatous disease, an inherited immune disorder, marking a gene therapy milestone.

Thank you, guys, for being here. Super excited to have an old friend join us for a new fireside chat. Allan, great to have you. And we all want to learn Prime Medicine and Prime Editing, but I'll let ...